Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies

Published on November 17, 2022 at 1:58 pm by Hamna Asim in Hedge Funds, News

In this article, we discuss the top 15 companies in Alphabet Inc (GOOGL)’s investment portfolio. If you want to see more names in this portfolio, check out Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies.

GV, previously named Google Ventures, is the venture capital investment arm of Alphabet Inc. (NASDAQ:GOOG), which was founded in 2009 by Bill Maris. GV provides seed, venture, and growth stage funding to startups in the Internet, software, life science, healthcare, artificial intelligence, transportation, cyber security, and agriculture sectors.

Though tech companies like Alphabet Inc. (NASDAQ:GOOG) have well-rounded investment divisions, others may not be as committed to their venture arms. With a US recession on the horizon, some venture capitalists are hesitant to keep pouring into startups while their own revenues and profits are dwindling.

GV currently has more than $8 billion in assets under management, with over 400 active portfolio investments across North America and Europe. Some of its prominent investment outcomes include Uber Technologies, Inc. (NYSE:UBER), GitLab Inc. (NASDAQ:GTLB), and Verve Therapeutics, Inc. (NASDAQ:VERV). To date, 65 of Alphabet-backed startups have had successful initial public offerings and 175 companies have been part of prominent M&A agreements.

Our Methodology

We used Alphabet’s latest SEC filings and picked GV Management’s investments dated November 15 to assess the biggest investments of the firm. The following list is ranked according to GV’s stake value in each firm.

Photo by Kai Wenzel on Unsplash

Alphabet Inc (GOOGL) Investment Portfolio: Top Companies

15. Illumina, Inc. (NASDAQ:ILMN)

Stake Value as of November 15: $9,858,000

Illumina, Inc. (NASDAQ:ILMN) is a California-based company that provides sequencing and array-based solutions for genetic and genomic analysis. The genomic solutions are utilized in research and clinical settings for life sciences, oncology, reproductive health, agriculture, and other emerging applications.

The venture capital arm of Google first invested in Grail, an American biotechnology company focusing on developing an early cancer screening test for people who do not have active symptoms. In September 2020, Illumina, Inc. (NASDAQ:ILMN) announced an agreement to purchase Grail for $7.1 billion. Currently, Alphabet’s GV Management holds a stake worth nearly $10 million in Illumina, Inc. (NASDAQ:ILMN).

Like Uber Technologies, Inc. (NYSE:UBER), GitLab Inc. (NASDAQ:GTLB), and Verve Therapeutics, Inc. (NASDAQ:VERV), Illumina, Inc. (NASDAQ:ILMN) is one of the premier holdings in the Alphabet investment portfolio.

Polen Capital made the following comment about Illumina, Inc. (NASDAQ:ILMN) in its Q3 2022 investor letter:

“Illumina, Inc. (NASDAQ:ILMN) has had a very difficult year on what we believe are transitory issues. First, the company closed its acquisition of Grail, a startup early-stage cancer testing business it re-acquired (Grail was founded inside Illumina originally) for $8 billion without regulatory approval. Illumina management believes that European regulators have no jurisdiction over the transaction as Grail had no European presence or revenue and member states did not complain within the timeframe specified in applicable regulations. The regulators have challenged these assertions and are likely to try to require Illumina to divest Grail subject to Illumina’s appeal. In the meantime, Grail has already been very dilutive to Illumina’s earnings, and Illumina may have to sell the asset at the end of it all. It is unknown how much Grail could be sold for in this environment if Illumina is forced to divest.

Second, Illumina’s core sequencing business has also slowed. This is not unusual as the business has always been a bit lumpy, but there are new competitors trying to prove that they can sequence genomes cheaper than Illumina without sacrificing accuracy. Our research here suggests: 1) competitor technologies do not seem to be as cost-effective or accurate in the real world as advertised, providing limited risk to Illumina’s core business; 2) Illumina has unveiled its own next-generation technology, which lowers the cost of sequencing the human genome to only $200, including data processing costs with world-class accuracy; 3) the slowdown in the core business is more macroeconomic as customers are looking to reduce consumables inventory levels in tough times and should pass quite quickly considering customers are continuing to use their sequencers at high levels; and 4) even if Illumina were forced to divest Grail, we think they would likely be able to sell it for above what it purchased it for as all of the clinical data on the company’s Galleri cancer screen is now publicly available (it is very positive in our view). Grail has made significant commercial progress since its acquisition, and the company should only be closer to U.S. regulatory approval. We believe we can buy the shares today at an extremely cheap valuation for the core business of a company that we view as having an unmatched position in a market that should be multiples of its current size in the years to come.”

14. IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Stake Value as of November 15: $10,394,000

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) was incorporated in 2015 and is headquartered in South San Francisco, California. It is a synthetic lethality-focused precision medicine oncology company, specializing in the discovery and development of targeted therapeutics using molecular diagnostics.

In March 2022, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) raised $94 million through a crossover round to start clinical trials for synthetic lethality and cancer immunotherapy. One of the leading stakeholders in this funding round was Alphabet’s GV. As of November 15, Alphabet’s IDEAYA Biosciences, Inc. (NASDAQ:IDYA) stake is valued at $10.3 million.

13. Beam Therapeutics Inc. (NASDAQ:BEAM)

Stake Value as of November 15: $12,449,000

Beam Therapeutics Inc. (NASDAQ:BEAM) is a Massachusetts-based biotechnology company that develops precision genetic medicines to combat serious diseases in the United States. In March 2019, Beam Therapeutics Inc. (NASDAQ:BEAM) completed a $135 million Series B financing round, bringing its total capital to $222 million in less than a year. Beam Therapeutics Inc. (NASDAQ:BEAM) planned to use proceeds from the financing for the advancement of its next-generation CRISPR technologies, expansion of its base editing pipeline, and further enhance its scientific and technical leadership. Alphabet’s GV Management was one of the most prominent investors of Beam. As of November 15, GV holds a $12.4 million stake in Beam Therapeutics Inc. (NASDAQ:BEAM).

Here is what Baron Health Care Fund has to say about Beam Therapeutics Inc. (NASDAQ:BEAM) in their Q1 2021 investor letter:

“Beam Therapeutics Inc. is a biotechnology company pioneering a novel technology called base editing, which allows for individual base pairs (the letters of DNA) to be modified. Shares fell along with other biotechnology stocks driven by a sudden rise in treasury yields. Early stage biotechnology stocks are particularly sensitive to interest rates because their cash flows are further in the future. We believe we are entering into a phase of significant advancement for the gene editing field that will eventually lead to curative therapies, and we think Beam has a unique platform technology.”

12. Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Stake Value as of November 15: $14,157,000

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) was incorporated in 2019 and is headquartered in Boston, Massachusetts. It is a biopharmaceutical company focused on the development of novel small molecule precision medicines. On March 12, 2021, Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) announced the conclusion of a $95 million Series C financing round. The company said that the proceeds will be utilized to take its lead development candidate into the clinic, quicken pipeline growth, and enhance its platform capabilities. One of the major participants in the financing round was Alphabet’s GV Management. GV, as of November 15, holds a $14 million position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE).

11. 23andMe Holding Co. (NASDAQ:ME)

Stake Value as of November 15: $16,707,000

23andMe Holding Co. (NASDAQ:ME) is a California-based consumer genetics testing company. It operates through two segments – Consumer & Research Services and Therapeutics. Google led the Series A round for 23andMe Holding Co. (NASDAQ:ME) and GV continued its investment all the way through 23andMe Holding Co. (NASDAQ:ME)’s Series E funding. As per latest filings on November 15, GV’s stake in 23andMe Holding Co. (NASDAQ:ME) amounted to $16.70 million.

10. Sana Biotechnology, Inc. (NASDAQ:SANA)

Stake Value as of November 15: $18,084,000

Sana Biotechnology, Inc. (NASDAQ:SANA) was incorporated in 2018 and is headquartered in Seattle, Washington. It is a biotechnology company focusing on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas such as oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders.

On June 23, 2020, Sana Biotechnology, Inc. (NASDAQ:SANA) raised $700 million in initial financing to advance the discovery and development of engineered cells as a treatment for different types of diseases. GV Management was one of the prominent contributors to the funding round. As of November 15, GV held a stake in Sana Biotechnology, Inc. (NASDAQ:SANA) worth about $18 million.

9. Toast, Inc. (NYSE:TOST)

Stake Value as of November 15: $18,539,000

Toast, Inc. (NYSE:TOST) is a Massachusetts-based company that operates a cloud-based and digital technology platform for the restaurant industry in the United States and Ireland. In January 2016, Toast, Inc. (NYSE:TOST) received $30 million in a round of Series B funding from GV and Bessemer Venture Partners. GV was the premier investor of Toast. As of November 15, Alphabet’s GV held a stake worth $18.5 million in Toast, Inc. (NYSE:TOST).

Here is what Baron Opportunity Fund has to say about Toast, Inc. (NYSE:TOST) in its Q3 2021 investor letter:

“Toast, Inc. is a cloud-based end-to-end technology platform purpose-built for the restaurant industry. Its platform provides a comprehensive suite of cloud software products and financial technology solutions to its customers to connect front-of-house with back-of-house operations across all customer channels. Toast’s core module is its point-of-sale software solution and requires all customers to use Toast as their payment processor. Customers then have the option to bundle or add-on additional modules across operations, digital ordering and delivery, marketing and loyalty, team management, and back office. Toast today powers 48,000 restaurants within the 860,000 U.S. restaurant industry, largely focusing on small- and medium-sized (“SMB”) restaurant customers (generally fewer than 10 locations but up to 50), with some larger enterprise customers as well. Toast is the clear market leader in SMB restaurant technology with the best product offering and only full, end-to-end platform. We believe that as restaurants continue to invest in technology at an accelerated pace emerging from COVID, Toast will be a big beneficiary given its leading market position and best-in-class product. At less than 6% penetration of U.S. restaurants and 3% penetration of its $15 billion recurring-revenue TAM, Toast has a long runway for growth by signing on additional locations to the platform and increasing the attach rate of its value-add modules. Only 54% of customers today use 4 or more of Toast’s 10-plus modules, each of which provide significant value to the customer and would drive Toast’s recurring revenue stream higher.”

8. Adagio Therapeutics, Inc.

Stake Value as of November 15: $18,633,000

Adagio Therapeutics, Inc. is a Massachusetts-based clinical-stage biopharmaceutical company, focused on the development and commercialization of antibody-based solutions for infectious diseases in the United States. Adagio Therapeutics, Inc. rebranded to Invivyd, Inc. (NASDAQ:IVVD) in September 2022.

On April 19, 2021, Adagio Therapeutics, Inc. closed a $336 million series C round, and one of the biggest investors was Alphabet’s GV Management. Latest filings reveal that Alphabet owns an $18.6 million stake in Adagio Therapeutics, Inc.

7. Desktop Metal, Inc. (NYSE:DM)

Stake Value as of November 15: $24,307,000

Desktop Metal, Inc. (NYSE:DM) is a Massachusetts-based company engaged in the manufacture and sale of additive manufacturing technologies for engineers, designers, and manufacturers in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. On February 6, 2017, Desktop Metal, Inc. (NYSE:DM) raised $45 million in new venture funding from the venture capital arms of Alphabet, BMW, and Lowe’s. As of November 15, Alphabet’s GV Management holds a $24.30 million stake in Desktop Metal, Inc. (NYSE:DM).

Miller Value Partners released its Q2 2021 investor letter, and mentioned Desktop Metal, Inc. (NYSE:DM). Here is what the firm said:

“Desktop Metals Inc. (DM) declined 21.29% during the period. The company reported their first quarter results with revenue of $11.3M beating consensus of $9.9M with adjusted EBITDA coming in at -$19.4B slightly ahead of consensus of -$20.6M. The company reaffirmed full year 2021 guidance with revenue expected in excess of $100M exiting the year at a revenue run rate of $160M but lowered adjusted EBITDA guidance to -$60M to -$70M from -$50m to -$60m previously. Over the period, the company announced a number of new processes and materials adding a process for wooden parts, the qualification of 316L stainless steel, qualification of 4140 low alloy-steel and the CE (Conformite Europeenne) mark for their Flexcera resin for use in 3D fabrication of dental prosthetics. By the end of the period, the company filed to sell 2.49M shares from existing shareholders.”

6. Relay Therapeutics, Inc. (NASDAQ:RLAY)

Stake Value as of November 15: $26,200,000

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a Massachusetts-based clinical-stage precision medicines company. It is engaged in transforming the drug discovery process with a focus on small molecule therapeutic discovery in targeted oncology and genetic disease indications. In December 2017, Relay Therapeutics, Inc. (NASDAQ:RLAY) completed a $63 million series B funding round, which was led by BVF Partners and backed by many investors including Alphabet’s GV. In December 2018, Relay raised $400 million in a series C round of funding led by SoftBank’s Vision Fund. Prominent investors in this funding round included Alphabet’s GV. As per latest filings, dated November 15, GV owns a position in Relay Therapeutics, Inc. (NASDAQ:RLAY) worth $26.20 million.

In addition to Uber Technologies, Inc. (NYSE:UBER), GitLab Inc. (NASDAQ:GTLB), and Verve Therapeutics, Inc. (NASDAQ:VERV), Relay Therapeutics, Inc. (NASDAQ:RLAY) is also backed by Alphabet Inc.

Click to continue reading and see Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up